Beyond ASH
Selina Luger, MD, FRCPC
Sagar Lonial, MD, FACP
Recently Presented Data of Clinical Trials in Patients with MM #BeyondASH21
Susan O'Brien, MD
; Recently Presented Data of Clinical Trials in Patients with CLL #BeyondASH21
Sonali Smith, MD, FASCO
Best Practices in Treating Aggressive Lymphomas #BeyondASH21
Nitin Jain, MD
Best Strategies for Incorporating Novel Agents, Combinations, and Sequencing of Agents/Regimens in the R/R Setting #BeyondASH21
Ruben Mesa, MD, FACP
Selection and Sequencing of JAK Inhibitors and Other Emerging Agents for MPNs #BeyondASH21
Nina Shah, MD
What Are the Latest Approaches for Using CAR T-cell Therapy for Hematologic Malignancies? #BeyondASH21
Kenneth Anderson, MD
Integrating Targeted Therapies for Relapsed/Refractory MM Into Practice #BeyondASH21
Michael Savona, MD
Recently Presented Data of Clinical Trials in Patients with MDS/MPNs #BeyondASH21
Eunice Wang, MD
How to Incorporate Emerging Novel Agents and Combinations in the R/R Setting for AML and ALL #BeyondASH21